⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NTHI News
NeOnc Technologies Holdings, Inc. Common Stock
Glafabra Therapeutics Receives FDA Orphan Drug Designation for GT-GLA-S03, Advancing a Redosable Cell Therapy for Fabry Disease Ready to Announce with Confidence?
newsfilecorp.com
OPFI
NTHI
Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI) Ready to Announce with Confidence?
newsfilecorp.com
NTHI
Form 8-K
sec.gov
NTHI
Form 8-K
sec.gov
NTHI
NeOnc Technologies Reports Phase 1 Dose-Escalation Results for Dosing and Toxicity and Determination of Recommended Phase 2 Dose for Oral NEO212; Management to Host KOL Conference Call Today at 9 a.m. ET
globenewswire.com
MRK
NTHI
Form 8-K
sec.gov
NTHI
Form 8-K
sec.gov
NTHI
NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Dose-Escalation Results from Full Phase 1 NEO212-01 Readout for Dosing and Toxicity
globenewswire.com
NTHI
New to The Street to Broadcast Executive Leadership Interviews Tonight at 6:30 PM EST on Bloomberg Television Across the U.S., MENA and Latin America
accessnewswire.com
NTHI
SNYR
YYGH
BIVI
VVOS
VTIX
New to The Street to Broadcast Show #726 on Bloomberg at 6:30 PM EST Featuring Vivos Therapeutics (NASDAQ:VVOS), Aeries Technology (NASDAQ:AERT), Virtuix Holdings (NASDAQ:VTIX), and Stardust Power (NASDAQ:SDST)
accessnewswire.com
VVOS
AERT
VTIX
SDST
SNYR
NTHI
YYGH